Randomized trial · people
Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This phase 3 trial shows weekly ecnoglutide alone lowered HbA1c more than placebo over 24 weeks in adults with type 2 diabetes, with a larger drop in the 1.2 mg arm.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 211
- Published
- 2026
- Journal
- Nat Commun
What they tested
The team tested whether once-weekly ecnoglutide, used on its own, lowers blood sugar better than placebo in adults with type 2 diabetes.
How the study was done
A randomized, double-blind, placebo-controlled phase 3 trial in 211 adults with type 2 diabetes at 32 centers in China, whose blood sugar was still too high on diet and exercise or one diabetes pill. They got a weekly shot of ecnoglutide 0.6 mg or 1.2 mg, or a matching placebo (a dummy shot), for 24 weeks.

What they found
After 24 weeks, HbA1c (an average of blood sugar over about 3 months) dropped 1.96% in the 0.6 mg arm and 2.43% in the 1.2 mg arm. The placebo group saw a drop of 0.87%. Compared with placebo, the 0.6 mg arm lowered HbA1c by an extra 1.09% (p = 0.0003) and the 1.2 mg arm by an extra 1.56% (p < 0.0001).
What it doesn’t show
The trial lasted 24 weeks and enrolled only people in China. It compared ecnoglutide with placebo, not with other diabetes or GLP-1 medicines.
The paper
Zhu et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026.
The compound
More studies on Ecnoglutide
- Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysisMeta-analysis · people · 2026
- Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutideRandomized trial · people · 2025
- Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg armRandomized trial · people · 2025
- Ecnoglutide: HbA1c fell up to 2.39% at 20 weeks in type 2 diabetesRandomized trial · people · 2024
- Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trialRandomized trial · people · 2023
- Every study on Ecnoglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.